Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Urological cancer

Is docetaxel the 'black widow' of mCRPC drugs?

Nature Reviews Clinical Oncology volume 12, pages 316–318 (2015)Cite this article

Subjects

In the recent MAINSAIL trial, addition of lenalidomide to docetaxel for metastatic castration-resistant prostate cancer (mCRPC) was associated with inferior overall survival and more toxicity; thus, lenalidomide joins a long line of agents that failed to improve the efficacy of docetaxel. The process by which new therapies are advanced to phase III studies, particularly in combination with docetaxel, should be re-examined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

    Article  CAS  Google Scholar 

  2. Petrylak, D. P. et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470–2045(15)70025–2 (2015).

  3. Kelly, W. K. et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30, 1534–1540 (2012).

    Article  CAS  Google Scholar 

  4. Tannock, I. F. et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 14, 760–768 (2013).

    Article  CAS  Google Scholar 

  5. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010).

    Article  CAS  Google Scholar 

  6. Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305–309 (2014).

    Article  CAS  Google Scholar 

  7. Nabhan, C. et al. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study. Clin. Genitourin. Cancer 12, 27–32 (2014).

    Article  Google Scholar 

  8. Petrylak, D. P. et al. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer [abstract]. J. Clin. Oncol. 27 (Suppl.), a5156 (2009).

    Google Scholar 

  9. Dahut, W. L. et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2532–2539 (2004).

    Article  CAS  Google Scholar 

  10. Lyman, G. H. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31, 2189–2204 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, 10029, NY, USA

    Bobby C. Liaw & William K. Oh

Authors
  1. Bobby C. Liaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William K. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William K. Oh.

Ethics declarations

Competing interests

W.K.O. has served in a consultancy or advisory relationship with Bayer, Dendreon, Janssen and Sanofi, and has received research funding from Sotio. B.C.L. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liaw, B., Oh, W. Is docetaxel the 'black widow' of mCRPC drugs?. Nat Rev Clin Oncol 12, 316–318 (2015). https://doi.org/10.1038/nrclinonc.2015.79

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.79

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing